Changeflow GovPing Pharma & Drug Safety Amerisource Meclizine Recall - Failed Tablet Sp...
Priority review Enforcement Added Final

Amerisource Meclizine Recall - Failed Tablet Specifications

Favicon for changeflow.com FDA: Drug Recalls Class II
Filed
Detected
Email

Summary

Amerisource Health Services LLC, distributed by American Health Packaging, initiated a Class II recall of Meclizine Hydrochloride Tablets, USP 12.5 mg nationwide. The recall (D-0418-2026) was initiated due to failed tablet specifications affecting products with NDC codes 60687-775-65 and 60687-775-11. The recall is ongoing with no specific return deadline provided.

What changed

Amerisource Health Services LLC, through American Health Packaging (Columbus, OH), initiated a Class II drug recall for Meclizine Hydrochloride Tablets, USP 12.5 mg. The recall affects two product configurations: 50-tablet bottles (NDC 60687-775-65) and individual dose units (NDC 60687-775-11). The reason for recall is failed tablet specifications. The recall has no specified return deadline and remains ongoing as of April 1, 2026.

Healthcare providers and pharmacies should immediately check inventory for the affected NDC codes and quarantine any remaining stock. Patients who have received this medication should be notified and advised to return the product to their pharmacy. Manufacturers and distributors in the supply chain should verify their records to identify potentially affected lots and coordinate with Amerisource for return procedures.

What to do next

  1. Verify inventory for NDC 60687-775-65 and 60687-775-11
  2. Quarantine and segregate any affected product found in stock
  3. Notify patients who may have received the recalled Meclizine 12.5mg tablets

Archived snapshot

Apr 7, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Amerisource Health Services LLC

Drug Recalls (Class II)

← All Drug Recalls (Class II) Class II D-0418-2026 · 20260401 · Ongoing

Product

Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets 5 x 10 (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Distributed by: American Health Packaging, Columbu...

Reason for Recall

Failed tablet specifications.

Distribution

U.S. Nationwide

Source: openFDA Enforcement API

Named provisions

Product Reason for Recall Distribution

Get daily alerts for FDA: Drug Recalls Class II

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Filed
April 1st, 2026
Instrument
Enforcement
Legal weight
Binding
Stage
Final
Change scope
Substantive
Document ID
Recall D-0418-2026

Who this affects

Applies to
Drug manufacturers Healthcare providers Patients
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Manufacturing Drug Distribution Pharmacy Dispensing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Compliance
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Product Safety Consumer Protection

Get alerts for this source

We'll email you when FDA: Drug Recalls Class II publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!